Please login to the form below

Not currently logged in
Email:
Password:

INC Research promotes Jamie Macdonald to CEO

Succession plan will see current CEO James Ogle remain as chairman

INC Research CEO Jamie MacdonaldINC Research has promoted its current chief operating officer Jamie Macdonald to president and CEO.

He will assume his new role at the contract research organisation (CRO) in January, 2013, when he takes over from James Ogle, who will continue to serve as chairman after also serving for nine years as INC's CEO and president.

James Ogle said: "I am proud of our accomplishments during my time at INC Research and the efforts of our many talented employees across the globe who are dedicated in their efforts every day to help our customers bring new life-saving and life-enhancing therapies to market.

"With integration behind us and INC Research solidly positioned for the future as a top-tier CRO, now is the time for me to transition away from the day-to-day leadership of the company and into the role of chairman." 

Macdonald joined INC Research as COO in 2011 as part of the company's acquisition of Kendle, where he served in this same capacity. He has more than 15 years of senior management experience in operational and financial roles in the CRO and biopharmaceutical industries.

Prior to joining Kendle, Jamie served as senior vice president and head of global project management at Quintiles.

Filling Macdonald's empty COO role from January will be Alistair Macdonald, who INC is promoting from president of clinical development services.

He joined INC in 2002 and, prior to his current role, served as head of the company's oncology therapeutic business unit.

21st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics